XML 111 R102.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
 [2]
Disclosure of operating segments [Line Items]    
Net income attributable to non-controlling interests [1] € 25 € 17
Fair value remeasurement of contingent consideration [1] (61) (66)
Restructuring costs and similar items [1] (430) (1,060) [3]
Other gains and losses, and litigation [1] (57) (450)
Operating income [1] 3,759 2,768
comprising: Financial expenses [1] (361) (583)
Financial income [1] 184 277
Income before tax and investments accounted for using the equity method [1] 3,582 2,462
Impairment loss on other intangible assets [1] 210 (371)
Other intangible assets    
Disclosure of operating segments [Line Items]    
Impairment loss on other intangible assets 210  
Impairment Loss on Intangible Asset Other Than Goodwill 210  
Operating segments    
Disclosure of operating segments [Line Items]    
Business operating income 5,363 4,938
Material reconciling items    
Disclosure of operating segments [Line Items]    
Share of profit/(loss) from investments accounted for using the equity method [4] (77) (66)
Net income attributable to non-controlling interests [5] 8 6
Amortization and impairment of intangible assets [6] (987) (527)
Fair value remeasurement of contingent consideration (61) (66)
Expense arising from the impact of acquisitions on inventories [7] 0 (7)
Restructuring costs and similar items [8] (430) (1,060)
Other gains and losses, and litigation [9] € (57) € (450)
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] Joint ventures and associates with which Sanofi has entered into a strategic alliance.
[5] Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
[6] The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €210 million in the first half of 2025 linked to research and development projects. As of June 30, 2024, this line includes a net reversal of impairment losses amounting to €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights.
[7] This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.
[8] See Note B.16.
[9] See Note B.17.